Compagnie Lombard Odier SCmA’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Hold |
0
| – | – | – | 672 |
|
|
2022
Q3 | – | Sell |
-600
| Closed | -$36K | – | 643 |
|
|
2022
Q2 | $36K | Hold |
600
| – | – | ﹤0.01% | 474 |
|
|
2022
Q1 | $38K | Sell |
600
-1,100
| -65% | -$69.7K | ﹤0.01% | 475 |
|
|
2021
Q4 | $128K | Sell |
1,700
-700
| -29% | -$52.7K | ﹤0.01% | 410 |
|
|
2021
Q3 | $268K | Buy |
2,400
+100
| +4% | +$11.2K | 0.01% | 315 |
|
|
2021
Q2 | $372K | Buy |
2,300
+1,525
| +197% | +$247K | 0.01% | 268 |
|
|
2021
Q1 | $95K | Buy |
775
+375
| +94% | +$46K | ﹤0.01% | 448 |
|
|
2020
Q4 | $61K | Buy |
+400
| New | +$61K | ﹤0.01% | 411 |
|
|
2018
Q4 | – | Sell |
-800
| Closed | -$35K | – | 542 |
|
|
2018
Q3 | $35K | Hold |
800
| – | – | ﹤0.01% | 445 |
|
|
2018
Q2 | $47K | Buy |
+800
| New | +$47K | ﹤0.01% | 433 |
|